BOOSTRIX-IPV (GlaxoSmithKline Australia Pty Ltd)

BOOSTRIX-IPV is indicated for booster vaccination against diphtheria, tetanus, pertussis and polio of individuals from the age of four years onwards.

BOOSTRIX-IPV is also indicated for passive protection against pertussis in early infancy following maternal immunisation during pregnancy.

Further guidance regarding the use of vaccines can be found in the Australian Immunisation Handbook.

Clinical data has demonstrated that in adults with an unknown history of pertussis vaccination, the majority had an immunogenic response to pertussis when given BOOSTRIX-IPV.

Finally, all adults who reach the age of 50 years without having received a boosting dose of dT in the previous 5 years should receive a further boosting dose of dT, where the adult/adolescent formulation dTpa can be used instead.

BOOSTRIX-IPV is not intended for primary immunisation.